A multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of user satisfaction and safety

Abstract

To compare user satisfaction and adverse events (AEs) with use of the 13.5 mg total content levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg) and a 30 μg ethinyl estradiol/3 mg drospirenone combined oral contraceptive (COC).